Skip to content
Trial Eligibility
Menu

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

NCT07867340

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also look at how the body absorbs, breaks down, and clears the study drug (pharmacokinetics), how the study drug works in the body, and whether it interacts with certain other medications by affecting how the body processes them.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • C-Reactive Protein

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 to 65 years
Sex
All
Healthy volunteers
Accepted
Sponsor
Eli Lilly and Company
Last updated on ClinicalTrials.gov
November 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Texas · 1

  • Fortrea Clinical Research Unit · Dallas, TX

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.